Andrew Perkins

25PUBLICATIONS
104CO-AUTHORS
Molecular targetsHaematological tumoursBioremediationDeep learningGenome structure and regulation
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jun 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

|May 08, 2026
Single cell long read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.

|Mar 26, 2026
Targeting enhancer RNAs to silence transcription.

Andrew Charles Perkins

|Mar 18, 2026
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE).

Francesco Passamonti, James M Foran, Anand Tandra

|Feb 03, 2026
DOT1L provides transcriptional memory through PRC1.1 antagonism.

Daniel Neville, Daniel T Ferguson, Emily B Heikamp

|May 07, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis.

David M Ross, Florian H Heidel, Andrew Charles Perkins

Pageof 5

Frequent Collaborators

3 joint publications

Vikas Gupta

3 joint publications

Jean-Jacques Kiladjian

2 joint publications

María Teresa Gómez Casares

2 joint publications

Naveen Pemmaraju